Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index; 7 of the 105 sources its claims cite were checked for support.

From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management

Open access
Pani, Arianna, Gironi, Ilaria, Di Vieste, Giacoma, Mion, Elena, Bertuzzi, Federico, Pintaudi, Basilio · 2020 · International Journal of Endocrinology

Abstract

Aims. Despite the very clear association between polycystic ovary syndrome (PCOS) and dysglycemia, few studies have explored the continuum of glycemic alterations leading from minor glucose abnormalities to overt diabetes. The purpose of this review is to trace the natural history of glycemic alteration in women with PCOS.Methods. We performed a literature review without time limit until August 2019. Inclusion criteria were studies addressing the association between impaired glucose tolerance or impaired fasting glucose or type 2 diabetes (T2D) and PCOS with at least an English abstract. The exclusion criteria were no PCOS or impaired glucose tolerance or impaired fasting glucose or T2D as outcome. The outcomes of interest were the onset of impaired glucose tolerance, impaired fasting glucose, T2D, and the progression from impaired glucose tolerance or impaired fasting glucose to T2D.Results. Healthy diet and physical activity are the first-line therapy for PCOS. Treatment with metformin was associated with significant lower 2-hour postload glucose levels and with reduction in fasting glucose when compared to placebo. Thiazolidinediones were more effective in reducing fasting glucose levels compared to placebo. Metformin and pioglitazone treatments showed similar effects on fasting glucose levels. The sodium-glucose cotransporter-2 inhibitor empagliflozin did not show differences in metabolic parameters when compared to metformin. The combination therapy with metformin plus the glucagon-like peptide-1 receptor agonist liraglutide was associated with significant improvements in basal and postload glucose levels compared with only liraglutide. Likewise, a combination therapy with the dipeptidyl peptidase-4 inhibitor saxagliptin and metformin demonstrated superiority versus metformin in fasting glucose and oral glucose tolerance test normalization. Myo-inositol supplementation was associated with lower insulin levels, glucose levels, and insulin resistance when compared with placebo, metformin, or estrogen treatments.Conclusions. The use of insulin-sensitizing agents, such as metformin and inositols, along with lifestyle interventions may improve the metabolic profile in PCOS women.

Overview

CoChat Summary

TL;DR

This narrative review traces the continuum of glycemic alterations in women with polycystic ovary syndrome (PCOS), from impaired glucose tolerance and impaired fasting glucose to type 2 diabetes, and summarizes lifestyle and pharmacological management options. It concludes that insulin-sensitizing agents such as metformin and inositols, combined with lifestyle intervention, may improve the metabolic profile in PCOS women.

Key findings

  • PCOS is associated with a two times increased risk for type 2 diabetes; impaired glucose tolerance prevalence is almost 30% in both adult women and affected adolescents, and insulin action is reduced by 35–40% in lean and obese women with PCOS versus controls.
  • Lifestyle modification (diet and physical activity) is the first-line therapy; for overweight women, lowering body mass by 5% can reduce serum insulin and testosterone levels and improve menstrual and reproductive function.
  • Metformin was associated with lower fasting glucose versus placebo or no treatment (MD −0.14 mmol/L; 95% CI −0.21 to −0.07) in one Cochrane meta-analysis, though a second meta-analysis of 13 RCTs and 506 subjects found no impact (MD −1.38 mmol/L; 95% CI −3.71, 0.94). In obese adolescents with PCOS and IGT, 8 of 15 normalized their OGTT (2-hour glucose 9.1 ± 0.3 vs. 7.4 ± 0.3 mmol/l; p = 0.005).
  • Thiazolidinediones were more effective than placebo in reducing fasting glucose (MD −0.55 mmol/l; 95% CI −1.06 to −0.05; p = 0.031) and showed similar effects to metformin (MD 0.21 mmol/l; 95% CI −0.46 to 0.03; p = 0.089). In one pioglitazone trial, 40% of patients with altered OGTT reverted to normality versus none in the placebo arm.
  • Empagliflozin showed no differences in metabolic parameters versus metformin, but favorable effects on body weight (−1.4 kg ± 3.2% vs. 1.2 kg ± 2.3%; p = 0.006) and BMI (p = 0.006). Metformin plus liraglutide improved OGTT at 0 and 120 min versus liraglutide alone (p = 0.015); saxagliptin plus metformin was superior to metformin for fasting glucose and OGTT normalization (p = 0.007), with 91% normalization in the combination arm.
  • Myo-inositol improved insulin resistance (HOMA index WMD −1.11; 95% CI −1.39–0.83; p < 0.00001 vs. placebo) and fasting insulin (WMD −3.97; 95% CI −5.76, −2.18; p < 0.00001 vs. placebo), though evidence for an effect on fasting glucose was not strong.

Methods

  • Literature review without time limit until August 2019, searching PubMed/Medline, Scopus, Web of Science, Science Direct, Embase, CINAHL, EBSCO, and Google Scholar using MeSH keywords for IGT, IFG, T2D, and PCOS.
  • Inclusion criteria: studies addressing the association between IGT, IFG, or T2D and PCOS with at least an English abstract, with focus on available PCOS treatment; exclusion criteria: no PCOS/IGT/IFG/T2D as outcome, conference presentations, and letters to editors.
  • All steps independently performed by two researchers, with disagreements resolved by a third researcher; outcomes of interest were onset of IGT, IFG, T2D, and progression from IGT/IFG to T2D.

Limitations

  • As stated by the authors: in most PCOS treatment trials the primary objectives are hormonal parameters, ovulatory function, or menstrual irregularities, so studies were underpowered to detect changes in metabolic parameters or diabetes prevention as secondary outcomes; very few studies analyze prediabetes treatment in PCOS and some are retrospective; most have small sample sizes and short observation times (not exceeding 24 weeks for longer studies).
  • Evident from the text: the review is narrative rather than systematic, with no formal risk-of-bias assessment or quantitative synthesis; several cited findings are drawn from single small trials or pilot studies (e.g., the 20-subject inositol T2D pilot, the 40-patient empagliflozin RCT), and the authors note that studies analyzing preventive effects from T2D in PCOS women are still lacking.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1155/2020/6276187

Cites

91 of 91 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

7 Valid · 1 Not valid · 70 Not checked · 18 Own results and interpretations

56 more claims · 2 with their cited sources checked

Create a free account to see all 96 claims and to verify the 98 references still open.

See all claims — free account
  • Probably not a substantial claim. 5
  • It may state two separate claims as one. 30
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

1 retracted

Show all 91 references

Research works printed but not linked: 2

  1. 2018, European Review for Medical and Pharmacological Sciences, 22, 6567
  2. 2012, European Review for Medical and Pharmacological Sciences, 16, 575

Cited by

See all 38

Metadata

Authors
Pani, A., Gironi, I., Di Vieste, G., Mion, E., Bertuzzi, F., & Pintaudi, B.
Affiliations
  • University of Milan (IT)
  • Diabetes Consultant, Milan, Italy
  • Diabetes Unit, Cantù Hospital, Abbiategrasso, Italy
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
Corresponding author
Pintaudi, Basilio
Venue
International Journal of Endocrinology
Publisher
Wiley
Published
2020-06-08
Volume
2020
Pages
1-10
ISSN
  • 1687-8337 (ISSN-L)
  • 1687-8345
OpenAlex
W3034163622
Cited by
38
References
91
Citations by year
2026: 2 · 2025: 5 · 2024: 4 · 2023: 9 · 2022: 8 · 2021: 6 · 2020: 3
FWCI
0.96
Type
journal article
Language
en
Open access
Locations
  • International Journal of Endocrinology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
polycystic ovary syndrome, type 2 diabetes, prediabetes, impaired glucose tolerance, impaired fasting glucose, dysglycemia, metformin, thiazolidinediones, pioglitazone, empagliflozin, liraglutide, saxagliptin, myo-inositol, insulin resistance, lifestyle intervention, physical activity, diet, insulin sensitizers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management. https://app.cochat.ai/papers/10.1155/2020/6276187
The paper
Pani, A., Gironi, I., Di Vieste, G., Mion, E., Bertuzzi, F., & Pintaudi, B. (2020). From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management. International Journal of Endocrinology. https://doi.org/10.1155/2020/6276187

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.